Section Arrow
VYNE.NASDAQ
- VYNE Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2026/04/10 20:14 EDT
Regular Hours
Last
 0.61
-0.0025 (-0.41%)
Day High 
0.6125 
Prev. Close
0.6125 
1-M High
0.63 
Volume 
101.07K 
Bid
0.6101
Ask
0.6248
Day Low
0.605 
Open
0.6125 
1-M Low
0.573 
Market Cap 
20.41M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.6 
20-SMA 0.6 
50-SMA 0.59 
52-W High 1.9933 
52-W Low 0.2805 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.62/-0.64
Enterprise Value
20.41M
Balance Sheet
Book Value Per Share
0.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
570.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.